Lilly kicks lobbying into high gear
Once again, Indianapolis-based Eli Lilly and Co. is running in the lead pack in dollars spent to bend ears on Capitol Hill. And that was even before the health care reform debate got rolling.
Eli Lilly and Co.
Articles
Peterson has passion for health care and new Lilly position
A new communications post at Eli Lilly gives former mayor Bart Peterson an opportunity to meld his experiences in the public
and private sectors.
VIEWPOINT: CEOs, do you deserve your salaries?
An exaggerated share of the nation’s wealth is paid to CEOs of public companies, their minions and directors, through agreements
made inside boardrooms, by highly compensated individuals who commit shareholders’ money and are not subject to effective
oversight.
With Byetta’s sales stalled, Lilly unveils its own competitor
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it’s developing a potential
competitor to Byetta all on its own.
Lilly, Simon receive top philanthropic awards
Two global companies based in Indianapolis have been recognized for their philanthropic efforts.
Keep Indianapolis Beautiful and Lilly team up on I-70 landscaping project
Some of Indianapolis’ main entrances from Interstate 70 are in line for a $2 million makeover.
With pharma famine looming, Lilly relying on snack-size deals
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
Obama’s reforms could bite Lilly
When it comes to health care reform, Eli Lilly and Co. has its derriere exposed more than its drugmaker peers.
In spite of criticism, Lilly saves lives
My wife, Becky, is alive today because of Lilly and its trial drug Enzastaurin, a great surgeon, and a terrific team of local doctors.
Executives make many trips to Washington to argue for 14 years of sales exclusivity for new drugs made from cells
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
from cells.
Lilly relying on technology to spot management talent
An electronic succession-planning system created by Eli Lilly & Co. about seven years ago is sniffing out top talent.
Are we victims of ‘group think’?
“Group think,” a powerful and controlling force, was present as the Capital Improvement Board built Lucas Oil Stadium and Eli Lilly and Co. developed and marketed Zyprexa.
Health care interests wary of state’s cost-cutting idea for Medicaid
Indiana Medicaid officials want to take over management of all its patients’ prescription drugs because they say it could save the state as much as $40 million a year.
Biotech push may help offset generic competition; some analysts skeptical
Lilly executives want to make biotech their top focus.
Lilly makes $6.5B acquisition
Eli Lilly and Co. CEO John Lechleiter played a game of pharmaceutical poker with former Lilly Chief Financial Officer Jim
Cornelius—and won.
Generic meds cost more than consumers realize
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
Lilly fighting with generic drug firms over Cymbalta, Alimta, 5 other medications
Eli Lilly & Co. has filed lawsuits against seven generic drug companies in federal court in Indianapolis, asking a judge to
declare its Cymbalta patent valid and to tell the generic companies to back off.
Despite sour economy, retail developers press on
Retail developers always have been an audacious breed. They spend millions to build shopping centers, confident that tenants will flock to fill the slots they didn’t prelease. To charge ahead these days takes more than the usual dose of intestinal fortitude. Everyone is nervous — from shoppers to lenders to retailers, many of which have […]
Eli Lilly investing $100M in China, hoping to attract research partners
Hoping to increase sales in China’s rapidly growing pharmaceutical market, Eli Lilly and Co. is charging ahead
with
plans to invest $100 million in venture capital in the region over the next several years.
Lilly buys ImClone as part of strategy to capitalize on cancer-drug market
Eli Lilly and Co. has written a $6.5 billion IOU to acquire the cancer drugs of ImClone Systems Inc. Cancer drugs are now
the best-selling class of drugs in the world and one of the fastest growing.